IL257983A - Improved transport of drugs into the brain - Google Patents
Improved transport of drugs into the brainInfo
- Publication number
- IL257983A IL257983A IL257983A IL25798318A IL257983A IL 257983 A IL257983 A IL 257983A IL 257983 A IL257983 A IL 257983A IL 25798318 A IL25798318 A IL 25798318A IL 257983 A IL257983 A IL 257983A
- Authority
- IL
- Israel
- Prior art keywords
- brain
- drugs
- enhanced delivery
- enhanced
- delivery
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217608P | 2015-09-11 | 2015-09-11 | |
| US201562247490P | 2015-10-28 | 2015-10-28 | |
| PCT/US2016/051128 WO2017044866A2 (en) | 2015-09-11 | 2016-09-09 | Enhanced delivery of drugs to the brain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL257983A true IL257983A (en) | 2018-05-31 |
Family
ID=58236547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL257983A IL257983A (en) | 2015-09-11 | 2018-03-08 | Improved transport of drugs into the brain |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11028155B2 (enExample) |
| EP (2) | EP3347380B1 (enExample) |
| JP (4) | JP2018531625A (enExample) |
| AU (2) | AU2016319133B2 (enExample) |
| CA (1) | CA2998132A1 (enExample) |
| IL (1) | IL257983A (enExample) |
| WO (1) | WO2017044866A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018531625A (ja) | 2015-09-11 | 2018-11-01 | ナセント バイオテック インコーポレイテッド | 脳への向上した薬物送達の方法 |
| US11492394B1 (en) | 2021-10-29 | 2022-11-08 | Nascent Biotech, Inc. | Kits and containers for treating vimentin expressing tumors |
| WO2023075790A1 (en) * | 2021-10-29 | 2023-05-04 | Nascent Biotech, Inc. | Kits and containers for treating vimentin expressing tumors |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| DE3223885A1 (de) | 1982-06-26 | 1983-12-29 | Basf Ag, 6700 Ludwigshafen | Makroporoese, hydrophile traeger fuer enzyme |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5004697A (en) * | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5651991A (en) | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
| JP2610792B2 (ja) | 1993-02-26 | 1997-05-14 | 株式会社ディ・ディ・エス研究所 | 多糖誘導体および薬物担体 |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| MX9504664A (es) | 1994-03-07 | 1997-05-31 | Dow Chemical Co | Conjugados de dendrimeros bioactivos y/o dirigidos. |
| WO1995025764A1 (en) | 1994-03-23 | 1995-09-28 | Meiji Seika Kabushiki Kaisha | Double-stranded derivative of polyoxyethylene-containing lipid |
| JP3699141B2 (ja) | 1994-09-24 | 2005-09-28 | 伸彦 由井 | 超分子構造の生体内分解性医薬高分子集合体及びその調製方法 |
| US5490840A (en) | 1994-09-26 | 1996-02-13 | General Electric Company | Targeted thermal release of drug-polymer conjugates |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6106866A (en) | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| WO2001080884A1 (en) * | 2000-04-25 | 2001-11-01 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| JP2007512846A (ja) * | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| CA2602316A1 (en) | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| WO2008028686A2 (en) * | 2006-09-10 | 2008-03-13 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| KR102276792B1 (ko) * | 2011-10-10 | 2021-07-15 | 시티 오브 호프 | 메디토프와 메디토프-결합 항체 및 이들의 용도 |
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| US20150218280A1 (en) * | 2012-08-10 | 2015-08-06 | University Of Southern California | CD20 scFv-ELPs METHODS AND THERAPEUTICS |
| GB201220242D0 (en) * | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
| JP2018531625A (ja) | 2015-09-11 | 2018-11-01 | ナセント バイオテック インコーポレイテッド | 脳への向上した薬物送達の方法 |
-
2016
- 2016-09-09 JP JP2018532523A patent/JP2018531625A/ja active Pending
- 2016-09-09 EP EP16845201.9A patent/EP3347380B1/en active Active
- 2016-09-09 US US15/261,725 patent/US11028155B2/en active Active
- 2016-09-09 CA CA2998132A patent/CA2998132A1/en active Pending
- 2016-09-09 EP EP24202128.5A patent/EP4548979A3/en not_active Withdrawn
- 2016-09-09 AU AU2016319133A patent/AU2016319133B2/en not_active Ceased
- 2016-09-09 WO PCT/US2016/051128 patent/WO2017044866A2/en not_active Ceased
-
2018
- 2018-03-08 IL IL257983A patent/IL257983A/en unknown
-
2021
- 2021-03-10 US US17/198,029 patent/US20210269513A1/en not_active Abandoned
- 2021-08-04 JP JP2021127980A patent/JP2021191269A/ja active Pending
-
2023
- 2023-06-27 JP JP2023104613A patent/JP7361980B2/ja active Active
- 2023-09-07 AU AU2023226718A patent/AU2023226718A1/en not_active Abandoned
- 2023-10-03 JP JP2023172056A patent/JP2024001124A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4548979A2 (en) | 2025-05-07 |
| JP7361980B2 (ja) | 2023-10-16 |
| JP2024001124A (ja) | 2024-01-09 |
| EP3347380A2 (en) | 2018-07-18 |
| AU2016319133B2 (en) | 2023-06-08 |
| EP3347380B1 (en) | 2024-09-25 |
| JP2018531625A (ja) | 2018-11-01 |
| JP2021191269A (ja) | 2021-12-16 |
| JP2023126840A (ja) | 2023-09-12 |
| AU2023226718A1 (en) | 2023-09-28 |
| US20170073400A1 (en) | 2017-03-16 |
| US11028155B2 (en) | 2021-06-08 |
| US20210269513A1 (en) | 2021-09-02 |
| WO2017044866A2 (en) | 2017-03-16 |
| EP4548979A3 (en) | 2025-07-23 |
| CA2998132A1 (en) | 2017-03-16 |
| HK1256875A1 (en) | 2019-10-04 |
| WO2017044866A3 (en) | 2017-06-08 |
| AU2016319133A1 (en) | 2018-04-05 |
| EP3347380A4 (en) | 2019-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3302565T3 (pl) | Stałe postacie dawkowane palbocyklibu | |
| SG11201702298VA (en) | Pharmaceutical preparation | |
| IL285882A (en) | Medicinal uses for l–4–chlorokynurenine | |
| ZA201608785B (en) | Nasal administration | |
| IL256115A (en) | Pharmaceutical formulations of injectable lapmoline | |
| GB2546139B (en) | Improvements relating to the manufacture of medical devices | |
| GB201419540D0 (en) | Delivery of drugs | |
| GB201400994D0 (en) | Drug delivery system | |
| IL259959A (en) | Oxygen-generating capsule | |
| GB201319437D0 (en) | Delivery of drugs | |
| IL252080B (en) | Oral administration of drugs that are unstable or poorly absorbed | |
| PT3878444T (pt) | N-(2-((2-benzilfenil)amino)-2-oxoetil)-l-naftamida) como agente terapêutico anticancro | |
| HRP20190230T1 (hr) | Lijek za liječenje vrtoglavice različitog podrijetla | |
| PH32016000973S1 (en) | Medicine injector | |
| TWM532871U (en) | Structure of medicine grinder | |
| GB201418061D0 (en) | Improvements to antimicrobial drugs | |
| PH32015000963S1 (en) | Medicine inhaler | |
| GB201601991D0 (en) | Medicine | |
| GB201504142D0 (en) | Option administration | |
| GB201522937D0 (en) | A combination of traditional chinese medicines for the treatment of cholecystitis | |
| GB201503733D0 (en) | New drug application | |
| GB201503731D0 (en) | New drug application | |
| AU358389S (en) | Pharmaceutical capsule | |
| GB201409272D0 (en) | Synergistic combination of analgesic drugs |